CYAD(Delisted)
Celyad Oncology·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYAD
Celyad Oncology Sa
A biotechnology company focused on chimeric antigen receptor T cell therapies for cancer
Axis Business Park Rue Andre Dumont 9, BE-1435 Mont-Saint-Guibert, Belgium
--
Celyad Oncology SA is a biotechnology company focused on discovering and developing innovative technologies for chimeric antigen receptor (CAR) T cell therapies. The company is focused on leveraging the true potential of its proprietary technology platform and intellectual property and supporting the development of next-generation CAR T drug candidates for solid tumors and hematological malignancies.
Company Financials
EPS
CYAD has released its 2022 Q2 earnings. EPS was reported at -0.3, versus the expected 0, missing expectations. The chart below visualizes how CYAD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
